Catch up on Jim Cramer's thinking over the last week about Bank of America's settlement and using trains as an indicator.
CVS dominates with its 'MinuteClinics,' leaving Walgreen in its dust as both face increasing competition from Wal-Mart and Target.
Enterprise Community Partners' report calls a $13 billion JPMorgan settlement 'reasonable' for consumers, but the report doesn't disclose that Enterprise receives substantial backing from the bank.
Valero Energy could bounce back with higher volume from the Gulf of Mexico and strength in ethanol segment.
Sprint cuts $20 from the price of its monthly unlimited data plan but changes some of the rules.
Emerging market pharmaceutical sales are exploding. Find out if Abbott Laboratories or Johnson & Johnson is best positioned to take advantage of the booming emerging market pharmaceutical market.
Biotech columnist Adam Feuerstein answers readers' questions about health care.